Evidence map›Paper›PMID 24607216›Full record

ArticleInternational journal of pharmaceutics2014

Dual-responsive polymer-coated iron oxide nanoparticles for drug delivery and imaging applications.

Varsha Sundaresan, Jyothi U Menon, Maham Rahimi, Kytai T Nguyen, Aniket S Wadajkar

Abstract read
In one paragraph

Article in International journal of pharmaceutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Microfabrication Technologies for Nanoinvasive and High-Resolution Magnetic Neuromodulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Fabrication of PNIPAm-based thermoresponsive hydrogel microwell arrays for tumor spheroid formation.Materials science & engineering. C, Materials for biological applications · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Varsha SundaresanDepartment of Bioengineering, The University of Texas at Arlington, Arlington, TX 76019, United States; Joint Biomedical Engineering Program between The University of Texas at Arlington and The University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.
Jyothi U MenonDepartment of Bioengineering, The University of Texas at Arlington, Arlington, TX 76019, United States; Joint Biomedical Engineering Program between The University of Texas at Arlington and The University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.
Maham RahimiDepartment of Vascular Surgery, University of Cincinnati, OH 45267, United States.
Kytai T NguyenDepartment of Bioengineering, The University of Texas at Arlington, Arlington, TX 76019, United States; Joint Biomedical Engineering Program between The University of Texas at Arlington and The University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.
Aniket S WadajkarDepartment of Bioengineering, The University of Texas at Arlington, Arlington, TX 76019, United States; Joint Biomedical Engineering Program between The University of Texas at Arlington and The University of Texas Southwestern Medical Center, Dallas, TX 75390, United States. Electronic address: aniketwadajkar@yahoo.com.

Funding

Novel Engineered Particle Platform for Endothelium RegenerationR01HL118498 · NHLBI · UNIVERSITY OF TEXAS ARLINGTON · PI NGUYEN, KYTAI TRUONG, YANG, JIAN · 2014 to 2017
$1.5M
NHLBI NIH HHS R01 HL118498
6 · The paper itself

Abstract

We reported the synthesis and characterization of dual-responsive poly(N-isopropylacrylamide-acrylamide-chitosan) (PAC)-coated magnetic nanoparticles (MNPs) for controlled and targeted drug delivery and imaging applications. The PAC-MNPs size was about 150nm with 70% iron mass content and excellent superparamagnetic properties. PAC-MNPs loaded with anti-cancer drug doxorubicin showed dual-responsive drug release characteristics with the maximum release of drugs at 40°C (∼78%) than at 37°C (∼33%) and at pH of 6 (∼55%) than at pH of 7.4 (∼28%) after 21 days. Further, the conjugation of prostate cancer-specific R11 peptides increased the uptake of PAC-MNPs by prostate cancer PC3 cells. The dose-dependent cellular uptake of the nanoparticles was also significantly increased with the presence of 1.3T magnetic field. The nanoparticles demonstrated cytocompatibility up to concentrations of 500μg/ml when incubated over a period of 24h with human dermal fibroblasts and normal prostate epithelial cells. Finally, pharmacokinetic studies indicated that doxorubicin-loaded PAC-MNPs caused significant prostate cancer cell death at 40°C than at 37°C, thereby confirming the temperature-dependent drug release kinetics and in vitro therapeutic efficacy. Future evaluation of in vivo therapeutic efficacy of targeted image-guided cancer therapy using R11-PAC-MNPs will reinforce a significant impact of the multifunctional PAC-MNPs on the future drug delivery systems.

Indexed as

Drug Delivery SystemsAcrylic ResinsAntibiotics, AntineoplasticCell Line, TumorCells, CulturedChitosanDiagnostic ImagingDoxorubicinEpithelial CellsFerric CompoundsFibroblastsHumansMagnetic PhenomenaMaleMetal NanoparticlesProstateAcrylic ResinsAntibiotics, AntineoplasticChitosanDoxorubicinFerric Compoundsferric oxidepoly-N-isopropylacrylamideChitosanDual-responsivenessIron oxide magnetic nanoparticlesPoly(N-isopropylacrylamide)Prostate cancer

Identifiers

PMID24607216
PMCPMC4642438

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.